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Summary Two mouse monoclonal antibodies (MoAbs), TP-1 and TP-3, previously shown in
immunohistochemical studies to react with osteosarcomas, were labelled with 1251 or 1311 and evaluated for
their ability to localise to human osteogenic sarcoma xenografts after intravenous injection. The radiolabelled
TP-1 and TP-3 MoAbs had immunoreactive fractions of 70% and 67%, respectively, and bound to target
cells with binding constants of 8.5 x 108 M-1 and 4.0 x 109 M-1, respectively. After injection of labelled TP-3
IgG, -16% of the dose x g- tissue was found in the tumour after 24 hours. Maximum tumour/blood
radioactivity ratios of 6-7 were achieved 3-4 days after antibody injection, while the ratios for the normal
tissues were < 1. The tumours could be clearly visualised by whole-body gamma scintigraphy without the
need for subtraction techniques. The TP-1 IgG accumulated to a large extent also in the spleen. Hence, with
this antibody the tumour was less well delineated from the adjacent normal tissues. However, the F(ab')2
fragments, derived from the TP-1 IgG, gave tumour/blood ratios up to -40 after 3-4 days and yielded sharp
gamma scintigrams of the tumour. Specificity of the antibody localisation was indicated by the lack of
accumulation in a contralateral melanoma xenograft and the failure of 2 isotype-matched irrelevant MoAbs
to localise to the sarcomas. With the F(ab')2 fragments satisfactory images could be obtained already after 16
hours. The results suggest that this preparation may be useful in clinical radioimmunodetection of osteogenic
sarcomas.
In recent years considerable efforts have been made to utilize human osteosarcoma cells, were produced as previously
monoclonal antibodies, MoAbs, in diagnosis and therapy of described (Bruland et al., 1986). The antibodies were purified
human cancers (see Schlom, 1986). Immunoscintigraphy of from ascites by affinity chromatography on a protein A-
tumours in patients has primarily been successful in Sepharose column (Pharmacia, Uppsala, Sweden). F(ab')2
melanoma (Larson et al., 1985; Siccardi et al., 1986), fragments of TP-1 were obtained by digestion with pepsin
colorectal cancer (Mach et al., 1980; Mach et al., 1983; for 8 h using a pepsin/IgG ratio of 3/100 (weight/weight)
Chatal et al., 1985), and ovarian cancer (Epenetos et al., (Parham, 1983).
1982; 1984). So far less work has been reported on the The purity of the antibody preparations was checked by
disgnostic use of MoAbs in sarcoma patients (Armitage et polyacrylamide gel electrophoresis (Laemmli, 1970), and by
al., 1986; Greager et al., 1986). However, preclinical studies ion exchange chromatography using FPLC (Pharmacia).
have been carried out on nude mice bearing xenografts of The antibodies were labelled with 1251 or 1311 by the
human osteosarcoma (Pimm et al., 1982; Nakamura et al., lodo-Gen method (Fraker & Speck, 1978). The labelled
1984) and a soft tissue sarcoma (Brown et al., 1985). proteins were purified by gel filtration on Sephadex G25
Recently we have isolated 2 new antisarcoma MoAbs, (Pharmacia). More than 95% of the eluted activity was
TP-1 and TP-3 (Bruland et al., 1986). In immunohistochemical precipitated by 10% trichloroacetic acid. The specific activity
studies these antibodies were found to be highly specific; ranged from 20 to 30yCi/,ug in different preparations.
they reacted only with certain subgroups of sarcomas, viz. The immunoreactive fraction of the radiolabelled MoAbs
osteosarcomas, malignant fibrous histiocytomas and some was determined by measuring the binding of antibody to
unclassified sarcomas, but not with the other types of human increasing concentrations of the OHS osteosarcoma cells and
tumours tested. Also they failed to bind to a wide range of carrying out linear extrapolation to binding at infinite
normal adult and foetal tissues. Only in the case of proximal antigen excess, as described by Lindmo et al. (1984). The
kidney tubules and myoepithelial cells was a weak staining binding constants were determined by Scatchard plots, using
seen. Preliminary studies indicate that the antibodies bind to OHS cells.
2 different epitopes present on the same cell surface antigen Two irrelevant mouse monoclonals, UPC-10 (Flow,
which has an apparent molecular weight of 105 kD Rockville, MD) of isotype IgG2a, and TP-0 (IgG2b),
(manuscript in preparation). developed in our laboratory, were used as negative controls.
In this paper we report studies on the tissue distribution of
the labelled TP-1 and TP-3 antibodies in athymic mice Xenografted human tumours
carrying human osteosarcomas. The purpose was to see
whether the localisation of the antibodies in the human The osteosarcoma tumour line TPX, and the malignant
tumour xenografts was sufficiently specific to warrant further melanoma FEMX, were originally established as xenografts
studies in patients. in BALB/c athymic (nu/nu) mice from fresh patient biopsy specimens as described by Fodstad et al. (1980). Another
osteogenic sarcoma xenograft, OHSX, had been established
by inoculating cells from the in vitro cell line OHS (Fodstad
Materialsand methods ~~~~~et al., 1986) into nude mice. The xenografts were maintained
Monoclonal antibodies ~~~~~by serial transplantation in the athymic animals. Fragments Monoclonal antibodies ~~~~of the tumour tissue (2 x 2 x 3 mm) were implanted sc in
Two monoclonal antibodies, TP-1 (IgG2a) and TP-3 both flanks. Experiments were carried out after 6-8 weeks.
(IgG2b), obtained by fusion of X-63Ag 865.3 mouse The tumours ranged in size from 100mg to 1 g.
myeloma cells with spleen cells from mice immunized with Immunofluorescence studies showed that cells from the
sarcoma xenografts, as well as the in vitro cultured OHS
sarcoma cells, expressed high levels of the antigen detected
Correspondence: A. Pihl. by the TP-1 and TP-3 MoAbs. Cells from the melanoma
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In vivo distribution oflabelled antibodies
The 1251-labelled antibodies (1 ,ug) in 0.2-0.4ml PBS were _
injected into the tail vein of mice bearing the sc OHSX ° 25
xenograft. After different periods of time, the animals (3-8 ,,
mice at each time point) were killed and tumour, blood and a 20 0
different tissues (liver, kidney, spleen, heart, lung, bone and
brain) were removed and the radioactivity was measured in a 15 0
multiwell-type gamma counter (LKB, Bromma, Sweden). In a
all instances the whole tumour, regardless of size, was X '°
examined. The radioactivity x g1 tumour or normal tissue 0
was expressed in % of the injected dose and also relative to - 0 5
that of the blood.
02 04 08 16 32
Scintigraphic analysis Inverse of cell concentration (ml 10-6)
The localisation of the antibodies to the tumour was studied Figure I Determination of the immunoreactive fraction of
also by immunoscintigraphy. One jug of the 131I-labelled radiolabelled TP-3 IgG. The labelled antibody was incubated
MoAbs was injected i.v. in .t.mour.bearing.nude.mice. In with increasing concentrations of the cells and the cell-bound M sOAbs was injected i.V. In tumour-brearing nude mice . In raiatvt g *eaehmd radioactivity was determined and plotted according to Lindmo et one case the mice had a sarcoma (TPX) in one flank and a al., (1984). The immunoreactive fraction (r) is determined at
melanoma (FEMX) in the other one. Anaesthetized animals infinite antigen excess by linear extrapolation to the ordinate.
were placed under a gamma camera equipped with a pin- r= 1/1.5=0.67.
hole collimator. A collimator-object distance that allowed
the whole animal (except the tail) to be included in the field
of view, was used. Scintigraphic images were obtained at Tissue distribution
different times after the injection. To block thyroid uptake
of free radioiodine, the mice received 0.1% saturated The radioactivity in the various tissues, at different times
potassium iodide in the drinking water, starting 2 days after administration of the antibodies, is presented in Table
before injection of the labelled antibodies. I. It is seen that, with all 3 antibody preparations, the
radioactivity x g- tissue was initially several fold higher in
the tumours than in the other tissues (with one notable
Results exception that will be discussed below). The radioactivity in the tumours was at its maximum already after 24h, at which
The immunoreactivefraction time it was about 10% to 16% of the injected dose xg-1.
It then declined, at different rates for the different antibody
The immunoreactivities of the radiolabelled monoclonal preparations. The tumours showed large individual varia-
antibodies were derived according to Lindmo et al. (1984) tions in their ability to accumulate and retain radioactivity,
from plots as shown in Figure 1. The immunoreactive as is evident from the standard deviations.
fraction of the TP-3 antibody was -67%. In similar The tissue distribution of the radioactivity and the change
experiments the immunoreactive fractions of TP-1 and the with time varied considerably for the different preparations
corresponding F(ab')2 fragments were found to be 70%, and (Table I). In the case of TP-3, the activity in the tumour was
55%, respectively. retained essentially unchanged for -3 days, whereupon it
Scatchard analysis showed that TP-1 and TP-3 MoAbs declined markedly. In the liver and kidney, the activities
had binding constants of about 8.5 x 108 M-1 and decreased only moderately during the first few days, and
4.0 x 109M-1, respectively (data not shown). These values then rather abruptly from day 3 to day 4. The radioactivity
are well in excess of those estimated in a theoretical study in the blood decreased sharply from day 2 on. The results
(Kennel et al., 1983) to be sufficient for antibodies to be imply that the tumour/blood ratio increased during the first
useful in drug targeting or tumour imaging. 3 days, as will be discussed below.
Table I Tissue distribution of 1251i-labelled MoAbs in athymic mice bearing a
human osteogenic sarcoma
Radioactivity (% ofinjected dose+s.d.)g ' tissue at
MoAb Tissue Day I Day 2 Day 3 Day 4
Tumour 16.3 +9.1 15.8 + 3.9 14.3 +2.1 6.64+ 3.78
Liver 1.9+0.7 2.1+0.5 1.6+1.2 0.46+0.04
TP-3 IgG Kidney 1.9+0.5 1.7+0.1 1.4+0.8 0.33+0.02
Spleen 3.1+0.3 1.9+0.7 1.9+1.2 0.29+0.06
Blood 6.7+ 1.7 5.3+1.1 2.7+41.6 1.03+0.08
Tumour 12.9+5.9 10.4+4.6 3.3+0.5 2.15+0.28
Liver 3.9+3.3 1.7+0.6 2.6+0.2 1.16+0.06
TP-1 IgG Kidney 1.2+0.3 1.4+0.3 0.9+0.1 0.55+0.04
Spleen 9.5+_8.3 4.0+_2.1 10.7+_3.6 4.82+ 1.87
Blood 3.1+1.0 4.4+1.8 2.4+0.2 1.31+0.03
Tumour 10.4+8.1 5.5+1.1 2.2+_0.5 0.95+0.84
Liver 1.0+0.3 0.2+0.03 0.1_+0.01 0.06+0.02
TP-1 F(ab')2 Kidney 1.6+0.6 0.5+0.4 0.2+0.02 0.21+0.02
Spleen 1.2+0.3 0.3+0.1 0.1+0.03 0.05+0.01
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In the case of TP-l IgG, a high spleen radioactivity was MoAbs, TP-0 and UPC-10, were used. With the TP-0 (IgG
found. In fact, in several animals the spleen radioactivity 2b), the results were in agreement with expectation inasmuch
exceeded that found in the tumour. Also the activity in the as the tissue/blood ratios were <I for both tumour and
liver was higher than after administration of the TP-3. normal tissues (not shown). Also in the case of UPC-10 (IgG
Conceivably, post-labelling aggregations could have 2a), there was no accumulation of radioactivity in the
contributed to the odd splenic uptake. However, this possi- tumour. With this antibody, one of the 4 tumour-bearing
bility is considered unlikely, as in some animals receiving mice showed an increased spleen/blood radioactivity ratio
the same preparation no abnormal splenic accumulation (1.9). The reason for this finding is not obvious. In all other
was seen. animals the tissue/blood ratios were close to or < 1.
Since unspecific uptake of antibodies in spleen and liver
may be associated with the Fc portion of IgG, we prepared Scintigraphic analysis
the F(ab')2 from the TP-1 IgG. With the fragments there On the basis of the results in Table I and Figure 2 it was
was no increased uptake in spleen and liver. The radio- antted the visultin TableoIca Figraft by
activity in the tumour declined more rapidly than after anticipated that visualization of osteosarcoma xenografts by
administration of the IgG preparation. However, the activity gamma scintigraphy should be feasible, at least with TP-3
in the blood disappeared at a much faster rate. For this IgG and the TP-1 F(ab')2 fragments
reason the tumour/blood radioactivity ratio, one significant Gamma camera images were recorded at different times
parameter in imaging, initially increased strongly with time, after i.v. injection of the different antibodies. In Figure 3 are
as illustrated below, shown scintigrams taken after 2 days. At this time the
The tissue/blood radioactivity ratios for tumour, spleen, absolute amounts of radioactivity in the tumour were still
liver and kidney are shown in Figure 2. To take into account appreciable (Table I) and the tumour/blood radioactivity
the large variations between individual animals in the ratios were relatively high (Figure 2). It is apparent that with
radioactivity of both tissues and blood, we computed, for TP-3 IgG (left panel), a distinct image of the tumour was
each animal, the radioactivity ratios and plotted the mean of obtained.
the values thus obtained. It is seen (Figure 2, left panel) that Also with TP-1 IgG, the tumour was clearly visible, but
in the case of TP-3, the tumour/blood radioactivity ratio the discrimination between the tumour and adjacent tissues
increased up to 6 in the course of 3 days and then was less satisfactory (middle panel) than with TP-3, as
remained essentially constant. For the other tissues, the expected from the tissue distribution studies shown in Table
ratios were in all cases <1 and in most cases <0.5. I. In a separate experiment in which the animals carried a
The striking differences in in ou bet the whole sarcoma in one flank and a melanoma in the other one, only
TP-1giand the corresponding F(ab')2 fragments becomes the sarcoma was visualised (not shown).
evident when the results in the middle and the right panel of The F(ab')2 fragments gave by far the most distinct
Figure 2 are compared. After administration of TP-l IgGp images. The scintigram in the right panel of Figure 3 shows
the tumour/blood ratio deereased with time after day 1, and that after 2 days the radioactivity was present almost
the spleen/blood ratio was very high. In contrast, with the exclusively in the tumour. Due to the rapid clearance of
F(ab')2 fragments, the tumour/blood ratio increased strongly labelled material from the blood, satisfactory images could
with time up to about 40 after 4 days, while concurrently the be obtained already after 16h, as shown in Figure 4.
spleen/blood ratio increased up to 3 only. In the latter case,
the kidney/blood ratio was higher than with the whole Discussion
antibody, probably due to renal elimination of labelled
material. For heart, lung, bone, and brain tissues (not The results reported in this preclinical study show that the 2
shown), the ratios were considerably < 1. mouse MoAbs, TP-1 and TP-3 previously shown in immuno-
In control experiments, 2 isotype-matched, irrelevant histochemical studies to bind with high specificity to human
7 TP-3 IgG 7; TP-1 IgG TP-1 F(ab')2
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Fagwe 3 Gamma camera images recorded 2 days after injection of 1 pg 13'I-labelled antibody. In the middle panel the bladder
contained urine with excreted labellEd material.
Completely different results were obtained with the F(ab')2
lw fragments derived from the intact TP-l (IgG 2a). In this case
the radioactivity in the normal tissues, including that in the
spleen, was low compared to that in the tumour. Due to the
rapid blood clarance of the radioactivity, the tumour/blood
ratios increased to as much as 40 in the course'of 3 to 4
days. Clearly defned scintigrams of the xenografted
sarcomas were obtained, despite the fact that the absolute
amounts of radioactivity retained in the tumours were
considerably lower than when the intact IgG was used.
Unfortunately, all attempts to prepare corresponding
fragments from TP-3, an IgG2b antibody, invariably led to
fturthfr cleavage.
In our study, like in that by Nakamura et al. (1984), large
individual differences in the amount of radioactivity present
in the tumours were found. Since we always measured the
radioactivity in the whole tumour, this variability can hardly
be due to sampling errors. Conceivably, the observed
variations were related to the fact that our xenografts varied
in size at the time of antibody administration and some of
the small tumours contained little viable tumour tissue. The
OHSX tumour here used displays a variable lag-time (2-4
weeks). The xenografts then start to grow at a relatively slow
rate with tumour volume doubling times (50 to 100mm3) of
-6 days. In contrast, the human sarcoma cell line HT-1080
used by Brown et al. (1985) in their study of a sarcoma
Fugwe 4 Gamma amera imuge recorded 16h after injection of antibody, grows rapidly and reproducibly in nude mic.
1pg 13 I-F(ab')2 fragments ofTP-1. Unfortunately, this cell line could not be used in our studies
since the cells failed to bind our antibodies.
The results obtained here with TP-3 IgG, and in particular
osteogenic sarcomas growing as xenografts in athymic nude those with the F(ab)2 fragments of the TP-1, seem to satisfy
mice. The findings that the TP-I IgG failed to localise in a several of the requirements that must be met for an antibody
contra-lateral melanoma xenograft, and that two irrelevant to be clinically useful. A high percentage of the aministered
MoAbs showed no significant accumulation in the sarcomas, dose was retained in the sarcomas with concurrent low
support the view that the observed accumulation of the accumulation of radioactivity in normal tissues, permitting
antibodies in the sarcomas largely reflected antigen-antibody clear visualization of the tumour without subtraction
binding. techniques. In fact, the accumulation of antibody radio-
It is of interest that the two anti-sarcoma MoAbs which activity in the tumour, relative to that in blood and normal
bind to the same antigen (Bruland, manuscript in tissues, was considerably higher in the present study than in
preparation), were found to differ considerably in their earlier investigations in which anti-sarcoma antibodies were
biological properties and potential clinical usefulness. After administered to sarcoma-bearing athymic mice. Thus,
injection of TP-3, the tumour/blood radioactivity ratio Nakamura et al. (1984) found tumour/blood radioactivity
inrased up to 6-7 on day 3, and with this antibody the ratios up to 4.3. 5-7 days after injection of antibodies Ost 6
sarcoma xenografts could easily be visualized by immuno- and Ost 7, and Brown et al. (1985) observed tumour/blood
scintigraphy. In contrast, after administration of the other ratios of 2.2-3.4 on day 7 with the antibody 19-24. Also the
MoAb, TP-I IgG, the tumour/blood radioactivity ratio tumour/blood ratios observed by Pimm et al. (1982) with the
deceae from day 1 on, and appreciable radioactivity wvas antibody 79IT/36 were considerably lower than those found
loclised in the spleen. For this reason the scintigraphic in the preset workc.
images of the sarcomas were poorly defined with inadequate lThe demonstration of a high and semingly seific uptakce
discrimination between the tumour tissue and the spenliver of the labelld MoAbs in human tulmour xeogafts in nude
region. mice is, however, no assurance that sucsfl imaging canIN VIVO LOCALISATION OF ANTI-SARCOMA MoAbs 25
be achieved in patients. The pharmacokinetics of mouse
antibodies differ in mice and humans, and the percentage of
the MoAb dose that accumulates per g of tumour tissue is
generally much lower in patients than in tumour-bearing
athymic mice, as emphasized by Epenetos et al. (1986).
Moreover, although our previous immunohistochemical
studies showed little binding to the normal tissues tested,
cross reactivity in vivo can not a priori be ruled out. On the
other hand, previous authors have been able to demonstrate
sarcoma images in patients with the aid of antibodies that in
nude mice gave lower tumour/blood ratios (Brown et al.,
1984; Pimm et al., 1982) and showed less tissue specificity
(Pim et al., 1982) than our antibodies. On this basis the
present results seem sufficiently encouraging to warrant
explorative studies of TP-3 IgG and TP-1 F(ab')2 in humans.
The demonstration that sharp gamma-images could be
obtained already after 16h, opens the possibility of using
radionuclides with short half-lives, such as 99mTc, and 1231,
which have excellent physical properties for the purpose of
imaging (Epenetos et al., 1982; Granowska et al., 1986).
Recently we have initiated immunoscintigraphic studies using
123I-labelled TP-1 F(ab')2 fragments in patients with
metastatic osteogenic sarcoma.
The authors thank Dr M. Aas for valuable help and discussions and
Mrs U. R0nning and Mrs M. Isaksen for excellent technical
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